Iterum Therapeutics Reports First Quarter 2025 Financial Results

Core Insights - Iterum Therapeutics is preparing for the potential launch of ORLYNVAH, an antibiotic for uncomplicated urinary tract infections (uUTIs), by Q4 2025 [2][6] - The company has extended its cash runway into 2026, ensuring sufficient funds for operations and pre-commercialization activities [4][6] Financial Performance - As of March 31, 2025, Iterum reported cash and cash equivalents of $12.7 million, with additional funds raised through offerings expected to support operations into 2026 [4][6] - The net loss for Q1 2025 was $4.9 million, a decrease from a net loss of $7.1 million in Q1 2024, indicating improved financial performance [9][18] - Non-GAAP net loss for Q1 2025 was $3.3 million compared to $5.8 million for the same period in 2024 [9][10] Operational Highlights - Research and development expenses for Q1 2025 were $0.6 million, significantly lower than $4.0 million in Q1 2024, reflecting a strategic focus on pre-commercialization activities [5][18] - General and administrative expenses increased to $2.8 million in Q1 2025 from $2.2 million in Q1 2024, primarily due to pre-commercialization spending [7][18] Strategic Focus - The company is actively seeking a strategic transaction for its rights to sulopenem while preparing for the launch of ORLYNVAH, emphasizing the urgency to address the lack of treatment options for uUTIs [2][6] - Iterum has received FDA approval for ORLYNVAH and is targeting a commercial launch to serve patients with limited treatment alternatives [6][14]